Vascular endothelial growth factor as a key inducer of angiogenesis in the asthmatic airways

Current Allergy and Asthma Reports

Volumn 13, Issue 1, 2013, Pages 1-9

  Meyer, Norbert ^a,b,c   Akdis, Cezmi A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Spital Netz Bern   (Switzerland)

^c Spital Ziegler   (Switzerland)

Author keywords

Airways; Angiogenesis; Asthma; IL 32; Inflammatory pathways; Interleukin 32; Novel therapies; Polymorphisms; Vascular endothelial growth factor; VEGF

Indexed keywords

4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; AE 941; AFLIBERCEPT; ALPHA INTERFERON; ANGIOPOIETIN 1; BECLOMETASONE; BEVACIZUMAB; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FIBRONECTIN; FLUTICASONE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; PLACENTAL GROWTH FACTOR; SALBUTAMOL; SILVER NANOPARTICLE; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN INHIBITOR;

ADVANCED CANCER; AIRWAY REMODELING; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ARTERIOLE; ARTICLE; ASTHMA; BLOOD FLOW VELOCITY; BLOOD VESSEL PERMEABILITY; CELL ACTIVITY; CELL DIFFERENTIATION; CELL HYPERPLASIA; CELL PROLIFERATION; CELL STIMULATION; CHRONIC INFLAMMATION; COLORECTAL CANCER; CYTOKINE PRODUCTION; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE CONTROL; DRUG MEGADOSE; DRUG PROTEIN BINDING; ENDOTHELIUM CELL; FIBROSIS; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GOBLET CELL; GOBLET CELL HYPERPLASIA; HUMAN; IMMUNE RESPONSE; INTRACELLULAR SIGNALING; LUNG BLOOD VESSEL; LUNG FIBROBLAST; LUNG VASOCONSTRICTION; LYMPHANGIOGENESIS; MUSCLE HYPERTROPHY; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; PROTEIN STRUCTURE; REGULATORY MECHANISM; RESPIRATORY TRACT INFLAMMATION; RETINA MACULA AGE RELATED DEGENERATION; RHINOVIRUS INFECTION; SENSITIZATION; SINGLE NUCLEOTIDE POLYMORPHISM; SPUTUM LEVEL; STEROID THERAPY; TH2 CELL; TREATMENT DURATION; VASCULAR DISEASE; VASCULAR ENDOTHELIUM; VASCULAR LEAKAGE; VASODILATATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ASTHMA; BRONCHIAL HYPERREACTIVITY; CAPILLARY PERMEABILITY; CELL DIFFERENTIATION; CELL PROLIFERATION; ENDOTHELIUM, VASCULAR; HUMANS; LUNG; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872604607     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-012-0317-9     Document Type: Article

References (101)

1. Dunnill MS. The pathology of asthma, with special reference to changes in the bronchial mucosa. J Clin Pathol. 1960;13:27-33.
2. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005;438(7070):932-6. (Pubitemid 43093958)
3. Detoraki A, Granata F, Staibano S, et al. Angiogenesis and lymphangiogenesis in bronchial asthma. Allergy. 2010;65(8):946-58.
4. Weis SM, Cheresh DA. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat Med. 2011;17(11):1359-70.
5. Liekens S, De Clercq E, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol. 2001;61(3):253-70. (Pubitemid 32126663)
6. Zanini A, Chetta A, Imperatori AS, et al. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respir Res. 2010;11:132.
7. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 1983;219(4587):983-5.
8. Senger DR, Connolly DT, Van de Water L, et al. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res. 1990;50(6):1774-8. (Pubitemid 20098819)
9. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76. (Pubitemid 36749215)
10. Koch S, Tugues S, Li X, et al. Signal transduction by vascular endothelial growth factor receptors. Biochem J. 2011;437(2):169-83.
11. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med. 2001;7(5):575-83. (Pubitemid 32448325)
12. Ziche M, Maglione D, Ribatti D, et al. Placenta growth factor-1 is chemotactic, mitogenic, and angiogenic. Lab Invest. 1997;76(4):517-31. (Pubitemid 27176106)
13. Luttun A, Tjwa M, Moons L, et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med. 2002;8(8):831-40.
14. Frieri M. Asthma concepts in the new millennium: update in asthma pathophysiology. Allergy Asthma Proc. 2005;26(2):83-8. (Pubitemid 40770067)
15. Frieri M. Advances in the understanding of allergic asthma. Allergy Asthma Proc. 2007;28(6):614-9.
16. Kumar SD, Emery MJ, Atkins ND, et al. Airway mucosal blood flow in bronchial asthma. Am J Respir Crit Care Med. 1998;158(1):153-6. (Pubitemid 28337173)
17. Li X, Wilson JW. Increased vascularity of the bronchial mucosa in mild asthma. Am J Respir Crit Care Med. 1997;156(1):229-33. (Pubitemid 27293194)
18. Vrugt B, Wilson S, Bron A, et al. Bronchial angiogenesis in severe glucocorticoid-dependent asthma. Eur Respir J. 2000;15(6):1014-21. (Pubitemid 30399269)
19. Barbato A, Turato G, Baraldo S, et al. Epithelial damage and angiogenesis in the airways of children with asthma. Am J Respir Crit Care Med. 2006;174(9):975-81. (Pubitemid 44684445)
20. Tigani B, Cannet C, Karmouty-Quintana H, et al. Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI. Am J Physiol Lung Cell Mol Physiol. 2007;292(3):L644-53. (Pubitemid 46376982)
21. Rydell-Tormanen K, Johnson JR, Fattouh R, et al. Induction of vascular remodeling in the lung by chronic house dust mite exposure. Am J Respir Cell Mol Biol. 2008;39(1):61-7. (Pubitemid 351883959)
22. Tormanen KR, Uller L, Persson CG, et al. Allergen exposure of mouse airways evokes remodeling of both bronchi and large pulmonary vessels. Am J Respir Crit Care Med. 2005;171(1):19-25. (Pubitemid 40051690)
23. Capetandes A, Horne NS, Frieri M. Dermatophagoides extract-treated confluent type II epithelial cells (cA549) and human lung mesenchymal cell growth. Ann Allergy Asthma Immunol. 2005;95(4):381-8. (Pubitemid 41483733)
24. Frieri M, Capetandes A. The effect of enantiomers of beta-agonists on myofibroblast-derived vascular endothelial growth factor and other matrix components in the presence of dust-mite extract. Allergy Asthma Proc. 2008;29(2):182-8.
25. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. J Allergy Clin Immunol. 2001;107(6):1034-8. (Pubitemid 32523344)
26. Asai K, Kanazawa H, Kamoi H, et al. Increased levels of vascular endothelial growth factor in induced sputum in asthmatic patients. Clin Exp Allergy. 2003;33(5):595-9. (Pubitemid 36629683)
27. Siddiqui S, Sutcliffe A, Shikotra A, et al. Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis. J Allergy Clin Immunol. 2007;120(4):813-9. (Pubitemid 47531832)
28. Abdel-Rahman AM, el-Sahrigy SA, Bakr SI. A comparative study of two angiogenic factors: vascular endothelial growth factor and angiogenin in induced sputum from asthmatic children in acute attack. Chest. 2006;129(2):266-71. (Pubitemid 43289843)
29. Mura M, dos Santos CC, Stewart D, et al. Vascular endothelial growth factor and related molecules in acute lung injury. J Appl Physiol. 2004;97(5):1605-17. (Pubitemid 39425973)
30. Lopez-Guisa JM, Powers C, File D, et al. Airway epithelial cells from asthmatic children differentially express proremodeling factors. J Allergy Clin Immunol;129(4):990-7 e6. The authors demonstrate that VEGF production is significantly greater in bronchial and nasal air-liquid interface cultures from asthmatic children than in cultures from atopic non-asthmatic and healthy children.
31. Simcock DE, Kanabar V, Clarke GW, et al. Induction of angiogenesis by airway smooth muscle from patients with asthma. Am J Respir Crit Care Med. 2008;178(5):460-8.
32. Clifford RL, John AE, Brightling CE, et al. Abnormal histone methylation is responsible for increased vascular endothelial growth factor 165a secretion from airway smooth muscle cells in asthma. J Immunol. 2012;189(2):819-31.
33. Fujita H, Chalubinski M, Rhyner C, et al. Claudin-1 expression in airway smooth muscle exacerbates airway remodeling in asthmatic subjects. J Allergy Clin Immunol. 2011;127(6):1612-21. e8.
34. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1. Circ Res. 1998;83(8):832-40. (Pubitemid 28489080)
35. Lee KS, Min KH, Kim SR, et al. Vascular endothelial growth factor modulates matrix metalloproteinase-9 expression in asthma. Am J Respir Crit Care Med. 2006;174(2):161-70. (Pubitemid 44015389)
36. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. J Allergy Clin Immunol. 2001;107(2):295-301. (Pubitemid 32173907)
37. de Paulis A, Prevete N, Fiorentino I, et al. Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. J Immunol. 2006;177(10):7322-31. (Pubitemid 44715102)
38. Sumbayev VV, Nicholas SA, Streatfield CL, et al. Involvement of hypoxia-inducible factor-1 HiF(1alpha) in IgE-mediated primary human basophil responses. Eur J Immunol. 2009;39(12):3511-9.
39. Chetta A, Zanini A, Foresi A, et al. Vascular endothelial growth factor up-regulation and bronchial wall remodelling in asthma. Clin Exp Allergy. 2005;35(11):1437-42.
40. Zanini A, Chetta A, Saetta M, et al. Chymase-positive mast cells play a role in the vascular component of airway remodeling in asthma. J Allergy Clin Immunol. 2007;120(2):329-33. (Pubitemid 47102382)
41. Sismanopoulos N, Delivanis DA, Alysandratos KD, et al. IL-9 induces VEGF secretion from human mast cells and IL-9/IL-9 receptor genes are overexpressed in atopic dermatitis. PLoS One. 2012;7(3):e33271.
42. Poulin S, Thompson C, Thivierge M, et al. Cysteinyl-leukotrienes induce vascular endothelial growth factor production in human monocytes and bronchial smooth muscle cells. Clin Exp Allergy. 2010;41(2):204-17.
43. Wen FQ, Liu X, Manda W, et al. TH2 Cytokine-enhanced and TGF-beta-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by IFN-gamma and corticosteroids. J Allergy Clin Immunol. 2003;111(6):1307-18. (Pubitemid 36683687)
44. Lee CG, Link H, Baluk P, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med. 2004;10(10):1095-103. (Pubitemid 39424871)
45. Calhoun WJ, Dick EC, Schwartz LB, et al. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest. 1994;94(6):2200-8. (Pubitemid 24379589)
46. Bufe A, Gehlhar K, Grage-Griebenow E, et al. Atopic phenotype in children is associated with decreased virus-induced interferon-alpha release. Int Arch Allergy Immunol. 2002;127(1):82-8. (Pubitemid 34224957)
47. Gehlhar K, Bilitewski C, Reinitz-Rademacher K, et al. Impaired virus-induced interferon-alpha2 release in adult asthmatic patients. Clin Exp Allergy. 2006;36(3):331-7. (Pubitemid 43344714)
48. Pritchard AL, Carroll ML, Burel JG, et al. Innate IFNs and Plasmacytoid Dendritic Cells Constrain Th2 Cytokine Responses to Rhinovirus: A Regulatory Mechanism with Relevance to Asthma. J Immunol. 2012;188(12):5898-905.
49. Psarras S, Volonaki E, Skevaki CL, et al. Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. J Allergy Clin Immunol. 2006;117(2):291-7. (Pubitemid 43190142)
50. Meyer N, Christoph J, Makrinioti H, et al. Inhibition of angiogenesis by IL-32: possible role in asthma. J Allergy Clin Immunol. 2012;129(4):964-73. e7.
51. Soyka MB, Treis A, Eiwegger T, et al. Regulation and expression of IL-32 in chronic rhinosinusitis. Allergy. 2012;67(6):790-8.
52. Nold-Petry CA, Nold MF, Zepp JA, et al. IL-32-dependent effects of IL-1beta on endothelial cell functions. Proc Natl Acad Sci U S A. 2009;106(10):3883-8.
53. Meyer N, Zimmermann M, Burgler S, et al. IL-32 is expressed by human primary keratinocytes and modulates keratinocyte apoptosis in atopic dermatitis. J Allergy Clin Immunol. 2010;125(4):858-65. e10.
54. Fort MM, Cheung J, Yen D, et al. IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity. 2001;15(6):985-95. (Pubitemid 34075378)
55. Tamachi T, Maezawa Y, Ikeda K, et al. IL-25 enhances allergic airway inflammation by amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol. 2006;118(3):606-14. (Pubitemid 44301386)
56. Petersen BC, Budelsky AL, Baptist AP, et al. Interleukin-25 induces type 2 cytokine production in a steroid-resistant interleukin-17RB + myeloid population that exacerbates asthmatic pathology. Nat Med. 2012;18(5):751-8.
57. Corrigan CJ, Wang W, Meng Q, et al. T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A. 2011;108(4):1579-84.
58. Palmer MT, Weaver CT. Autoimmunity: increasing suspects in the CD4+ T cell lineup. Nat Immunol. 2009;11(1):36-40.
59. Maniati E, Soper R, Hagemann T. Up for Mischief? IL-17/Th17 in the tumour microenvironment. Oncogene;29(42):5653-62.
60. Kudo M, Melton AC, Chen C, et al. IL-17A produced by alphabeta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction. Nat Med. 2012;18(4):547-54.
61. Akdis M, Palomares O, van de Veen W, et al. TH17 and TH22 cells: a confusion of antimicrobial response with tissue inflammation versus protection. J Allergy Clin Immunol. 2012;129(6):1438-49. quiz1450-1.
62. Numasaki M, Lotze MT, Sasaki H. Interleukin-17 augments tumor necrosis factor-alpha-induced elaboration of proangiogenic factors from fibroblasts. Immunol Lett. 2004;93(1):39-43. (Pubitemid 38591518)
63. Chauhan SK, Jin Y, Goyal S, et al. A novel pro-lymphangiogenic function for Th17/IL-17. Blood. 2011;118(17):4630-4.
64. Hahn RG. Endotoxin boosts the vascular endothelial growth factor (VEGF) in rabbits. J Endotoxin Res. 2003;9(2):97-100. (Pubitemid 36603683)
65. Kim YS, Hong SW, Choi JP, et al. Vascular endothelial growth factor is a key mediator in the development of T cell priming and its polarization to type 1 and type 17 T helper cells in the airways. J Immunol. 2009;183(8):5113-20.
66. Choi JP, Kim YS, Tae YM, et al. A viral PAMP double-stranded RNA induces allergen-specific Th17 cell response in the airways which is dependent on VEGF and IL-6. Allergy. 2010;65(10):1322-30.
67. Bilton RL, Booker GW. The subtle side to hypoxia inducible factor (HIFalpha) regulation. Eur J Biochem. 2003;270(5):791-8. (Pubitemid 36315322)
68. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharmacol. 2000;59(1):47-53.
69. Kim SR, Lee KS, Park HS, et al. HIF-1alpha inhibition ameliorates an allergic airway disease via VEGF suppression in bronchial epithelium. Eur J Immunol. 2010;40(10):2858-69.
70. Lee YC, Jogie-Brahim S, Lee DY, et al. Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-kappaB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem. 2011;286(20):17898-909.
71. Kim SR, Lee KS, Lee KB, et al. Recombinant IGFBP-3 inhibits allergic lung inflammation, VEGF production, and vascular leak in a mouse model of asthma. Allergy. 2012;67(7):869-77.
72. Huerta-Yepez S, Baay-Guzman GJ, Bebenek IG, et al. Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis. Allergy. 2011;66(7):909-18.
73. Sharma S, Murphy AJ, Soto-Quiros ME, et al. Association of VEGF polymorphisms with childhood asthma, lung function and airway responsiveness. Eur Respir J. 2009;33(6):1287-94.
74. Simpson A, Custovic A, Tepper R, et al. Genetic variation in vascular endothelial growth factor-a and lung function. Am J Respir Crit Care Med;185(11):1197-204.
75. Balantic M, Rijavec M, Skerbinjek Kavalar M, et al. Asthma Treatment Outcome in Children Is Associated with Vascular Endothelial Growth Factor A (VEGFA) Polymorphisms. Mol Diagn Ther. 2012;16(3):173-80.
76. Simpson A, Custovic A, Tepper R, et al. Genetic variation in vascular endothelial growth factor-a and lung function. Am J Respir Crit Care Med. 2012;185(11):1197-204.
77. Li J, Huang J, Dai L, et al. miR-146a, an IL-1beta responsive miRNA, induces vascular endothelial growth factor and chondrocyte apoptosis by targeting Smad4. Arthritis Res Ther. 2012;14(2):R75.
78. Chen Y, Gorski DH. Regulation of angiogenesis through a microRNA (miR-130a) that down-regulates antiangiogenic homeobox genes GAX and HOXA5. Blood. 2008;111(3):1217-26. (Pubitemid 351213403)
79. Anand S, Majeti BK, Acevedo LM, et al. MicroRNA-132-mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med. 2010;16(8):909-14.
80. Liu B, Peng XC, Zheng XL, et al. MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer. 2009;66(2):169-75.
81. Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell. 2008;15(2):272-84.
82. Song C, Ma H, Yao C, et al. Alveolar macrophage-derived vascular endothelial growth factor contributes to allergic airway inflammation in a mouse asthma model. Scand J Immunol. 2012;75(6):599-605.
83. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31(1):143-78.
84. Hoshino M, Takahashi M, Takai Y, et al. Inhaled corticosteroids decrease vascularity of the bronchial mucosa in patients with asthma. Clin Exp Allergy. 2001;31(5):722-30. (Pubitemid 32823816)
85. Chetta A, Zanini A, Foresi A, et al. Vascular component of airway remodeling in asthma is reduced by high dose of fluticasone. Am J Respir Crit Care Med. 2003;167(5):751-7. (Pubitemid 36801754)
86. Wang K, Liu CT, Wu YH, et al. Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within airway remodelling in asthma. Adv Ther. 2008;25(4):342-54.
87. Feltis BN, Wignarajah D, Reid DW, et al. Effects of inhaled fluticasone on angiogenesis and vascular endothelial growth factor in asthma. Thorax. 2007;62(4):314-9. (Pubitemid 46580574)
88. Akdis CA. Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med. 2012;18(5):736-49.
89. Dupont E, Savard PE, Jourdain C, et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg. 1998;2(3):146-52. (Pubitemid 28266271)
90. Lee SY, Paik SY, Chung SM. Neovastat (AE-941) inhibits the airway inflammation and hyperresponsiveness in a murine model of asthma. J Microbiol. 2005;43(1):11-6.
91. Lee SY, Chung SM. Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression. Vascul Pharmacol. 2007;47(5-6):313-8. (Pubitemid 350008133)
92. He K, Cui B, Li G, et al. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther. 2012;5:59-65.
93. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology. 2005;112(6):1035-47. (Pubitemid 40797459)
94. Lee YC, Kwak YG, Song CH. Contribution of vascular endothelial growth factor to airway hyperresponsiveness and inflammation in a murine model of toluene diisocyanate-induced asthma. J Immunol. 2002;168(7):3595-600. (Pubitemid 34250430)
95. Kim SR, Lee KS, Park SJ, et al. Inhibition of p38 MAPK reduces expression of vascular endothelial growth factor in allergic airway disease. J Clin Immunol. 2012;32(3):574-86.
96. Powers KW, Brown SC, Krishna VB, et al. Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of nanoscale particles for toxicological evaluation. Toxicol Sci. 2006;90(2):296-303.
97. Tsuji JS, Maynard AD, Howard PC, et al. Research strategies for safety evaluation of nanomaterials, part IV: risk assessment of nanoparticles. Toxicol Sci. 2006;89(1):42-50. (Pubitemid 43013753)
98. Syed S, Zubair A, Frieri M. Immune Response to Nanomaterials: Implications for Medicine and Literature Review. Curr Allergy Asthma Rep.
99. Kalishwaralal K, Banumathi E, Ram Kumar Pandian S, et al. Silver nanoparticles inhibit VEGF induced cell proliferation and migration in bovine retinal endothelial cells. Colloids Surf B Biointerfaces. 2009;73(1):51-7.
100. Jang S, Park JW, Cha HR, et al. Silver nanoparticles modify VEGF signaling pathway and mucus hypersecretion in allergic airway inflammation. Int J Nanomedicine. 2012;7:1329-43. The authors demonstrate that silver nanoparticles substantially suppressed mucus hypersecretion and the PI3K/HIF-1α/VEGF signaling pathway in an allergic airway inflammation.
101. Scarino A, Noel A, Renzi PM, et al. Impact of emerging pollutants on pulmonary inflammation in asthmatic rats: ethanol vapors and agglomerated TiO(2) nanoparticles. Inhal Toxicol. 2012;24(8):528-38.